Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amphastar Pharmaceuticals Inc (AMPH) vs Coupang Inc (CPNG) Price & Performance

Amphastar Pharmaceuticals IncTrade
Coupang IncTrade

Price performance (Past 24H)

Key statistics

Amphastar Pharmaceuticals Inc vs Coupang Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.91 (market cap $868.62M), while Coupang Inc trades at $16.51 (market cap $29.66B). The key difference: Coupang Inc is far larger — about 34.1× Amphastar Pharmaceuticals Inc's market cap, and Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, Coupang Inc nearer its low. Which is the better fit depends on your goals.

AMPHCPNG
Market Cap
$868.62M$29.66B
Sector
HealthConsumer Cyclical
52-Week High
$30.81$33.53
52-Week Low
$16.87$15.12
Enterprise Value
$1.27B$29.18B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amphastar Pharmaceuticals Inc

AMPH trades at $19.87, down 2.19% today, with a bullish technical signal from moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.91, beating expectations, but missed in Q4 2025 and Q1 2026. Revenue for 2025 was $719.89M with a net income margin of 10.76%, while valuation ratios like P/E of 12.08 and EV/EBITDA of 6.57 suggest reasonable pricing. Recent news highlights growth from new product launches and ongoing FDA compliance efforts.

The outlook is mixed with growth opportunities from proprietary drugs and biosimilars, but risks include regulatory scrutiny and earnings volatility. Analyst sentiment is cautious with 25% buy ratings, reflecting concerns over execution and market pressures. Investors should weigh solid cash flow generation against competitive and regulatory headwinds for balanced exposure.

Coupang Inc

CPNG trades at $16.19, down 0.25% on the day, with a bearish technical signal and recent earnings misses. Revenue grew to $34.53B in 2025, but net income margin remains thin at 0.6%. The stock is undervalued on a P/S basis at 0.85, yet high P/E and EV/EBITDA ratios reflect profitability challenges. Analyst consensus is strongly bullish with an average price target of $23.38, suggesting significant upside. Recent news highlights recovery from a data breach and expansion in Taiwan, though a $422M fine in South Korea poses regulatory risks.

The outlook hinges on execution in new markets and margin improvement. Upside potential exists if CPNG meets growth targets and reverses recent earnings underperformance, but investors face risks from competitive pressures, regulatory scrutiny, and volatile cash flows. The stock's current discount to analyst targets presents a opportunity, but sustained profitability is key to unlocking value.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amphastar Pharmaceuticals Inc

Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.

Read more on AMPH

About Coupang Inc

Coupang Inc is an e-commerce company. The company sells apparel, electronics, footwear, food products, furniture, nutritional supplements, and other products. Its segments include Product Commerce and Growth Initiatives.

Read more on CPNG